Overview
Amoxapine, the N-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H receptors, α-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Amoxapine may be used to treat neurotic and reactive depressive disorders, endogenous and psychotic depression, and mixed symptoms of depression and anxiety or agitation.
Indication
For the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. May also be used to treat depression accompanied by anxiety or agitation.
Associated Conditions
- Agitation
- Anxiety
- Depression, Endogenous
- Neurotic depression
- Psychotic Depression
- Reactive depression
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|
No clinical trials found
No clinical trials found for this drug
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Actavis Pharma, Inc. | 0591-5713 | ORAL | 25 mg in 1 1 | 2/28/2015 | |
Chartwell RX, LLC | 62135-703 | ORAL | 150 mg in 1 1 | 9/8/2023 | |
Chartwell RX, LLC | 62135-701 | ORAL | 50 mg in 1 1 | 9/8/2023 | |
Actavis Pharma, Inc. | 0591-5714 | ORAL | 50 mg in 1 1 | 2/28/2015 | |
Physicians Total Care, Inc. | 54868-2438 | ORAL | 50 mg in 1 1 | 5/16/2011 | |
Actavis Pharma, Inc. | 0591-5716 | ORAL | 150 mg in 1 1 | 2/28/2015 | |
Actavis Pharma, Inc. | 0591-5715 | ORAL | 100 mg in 1 1 | 2/28/2015 | |
Chartwell RX, LLC | 62135-700 | ORAL | 25 mg in 1 1 | 9/8/2023 | |
Chartwell RX, LLC | 62135-702 | ORAL | 100 mg in 1 1 | 9/8/2023 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
ASENDIN - TAB 25MG | wyeth-ayerst canada inc. | 02169886 | Tablet - Oral | 25 MG / TAB | 2/4/1997 |
ASENDIN TAB 50MG | lederle cyanamid canada inc. | 00527092 | Tablet - Oral | 50 MG / TAB | 12/31/1981 |
ASENDIN - TAB 100MG | wyeth-ayerst canada inc. | 02169908 | Tablet - Oral | 100 MG | 4/12/1999 |
ASENDIN TAB 25MG | lederle cyanamid canada inc. | 00527084 | Tablet - Oral | 25 MG / TAB | 12/31/1981 |
ASENDIN TAB 100MG | lederle cyanamid canada inc. | 00527106 | Tablet - Oral | 100 MG / TAB | 12/31/1981 |
ASENDIN - TAB 50MG | wyeth-ayerst canada inc. | 02169894 | Tablet - Oral | 50 MG / TAB | 4/29/1997 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.